Press Releases

Receive E-mail Alerts
25 May 2020 at 7:00 AM EDT
Summary ToggleProQR Announces Annual Meeting of Shareholders
Leiden, Netherlands & Cambridge, Mass. , May 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that the Annual General
7 May 2020 at 7:00 AM EDT
Summary ToggleProQR Announces First Quarter 2020 Operating and Financial Results
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned; Updated data from the Phase 1/2 InSight extension study of sepofarsen, including data from
31 March 2020 at 6:00 AM EDT
Summary ToggleProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse events QR-421a is the second ophthalmology program where clinical activity was predicted by translational
25 March 2020 at 4:15 PM EDT
Summary ToggleProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
LEIDEN, Netherlands & CAMBRIDGE, Mass. , March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that Company management will present and
26 February 2020 at 7:00 AM EST
Summary ToggleProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021 Phase 1/2 Stellar trial initiated for QR-421a
24 February 2020 at 7:00 AM EST
Summary ToggleProQR to Present at Cowen and Company 40th Annual Health Care Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that Company management
6 February 2020 at 7:00 AM EST
Summary ToggleProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases
My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S. LEIDEN, Netherlands and CAMBRIDGE, Mass , Feb. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for
30 January 2020 at 7:00 AM EST
Summary ToggleProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a
Designation is for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 30, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of